News

Stop TB Partnership Craig David Video Series #3

In a newly released clip – the third in a series of videos shot in South Africa during his first country visit as a Goodwill Ambassador against Tuberculosis – British R&B star Craig David talks with Dr Sizulu Moyo, a tuberculosis researcher at Stellenbosch University.

Dr Sizulu Moyo

Dr Sizulu Moyo

Against the backdrop of a busy research laboratory, Craig learns that lots of progress has been made and momentum gained in the diagnosis and treatment of tuberculosis thanks to collaboration among partners as well as increased awareness and commitment from poor and rich countries alike, spurred by the link between tuberculosis and HIV/AIDS: tuberculosis is the leading infectious killer of people living with HIV.

Two key challenges mentioned by Dr Moyo are the need for sufficient funding to develop an effective vaccine and the need for tuberculosis patients to complete their course of treatment (which lasts 6 months or more) to keep the medicines effective: incomplete treatment will lead to the tuberculosis bacteria becoming drug-resistant. While people are aware that they should finish treatment, she explains, “it’s a complicated scenario; there are many things that come into play…We need understand where they are coming from. They are people with lives, with families.”

Despite her laboratory surroundings Dr Moyo remains very aware of the real-life implications of her research: “It’s not only about the documents that you read, any nice brochures, it’s not about the presentations that you make… TB affects real people, real families and real communities.”

More News
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...